- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00992745
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Očekávaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
California
-
Laguna Niguel, California, Spojené státy, 92677
- West Coast Radiology Centers
-
Newport Beach, California, Spojené státy, 92663
- Pacific Coast Imaging
-
San Francisco, California, Spojené státy, 94143
- University of California - San Francisco
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland
-
-
New York
-
New York, New York, Spojené státy, 10065
- New York Presbyterian Hospital - Weill Cornell Medical College
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- Vanguard Urologic Research Foundation
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Subjects must meet all of the following criteria to be enrolled in this study.
- Male aged 18 years or older
- Signed written informed consent and willingness to comply with protocol requirements
- Histologic diagnosis of prostate cancer by validated history and/or biopsy of the prostate or of a metastatic lesion.
Evidence of metastatic disease as documented by an abnormal bone scan and CT scan or MRI plus:
Castration/anti androgen therapy naïve/sensitive:
- Gleason Score ≥ 7 and PSA ≥ 2.0 ng/mL with history of prostatectomy or primary radiation therapy of the prostate gland and prior undetectable PSA or; PSA > 10.0 ng/mL if intact prostate, or
- Gleason score ≤ 6 and PSA is ≥ 20 ng/mL, or
- Gleason Score ≥ 8 and any doubling of PSA, or PSA > 0.5 ng/mL, or
- Clinical Stage 3 and Gleason Score ≥ 8
If on anti androgen therapy, must have initiated therapy at least 4 weeks prior to treatment.
Castration/anti androgen therapy resistant:
- Patients must have current or historical evidence of disease progression concomitant with surgical (orchiectomy) or medical castration (LHRH analogue); anti androgen withdrawal (4 weeks for flutamide and 6 weeks for nilutamide or bicalutamide) is necessary only for patients on anti androgens who have demonstrated a > 3 month duration of beneficial response to anti androgens; progression is demonstrated by any of the following:
I. PSA progression: 2 serial rising PSA determinations at least 14 days apart over the PSA nadir, with the last measurement ≥ 2 ng/mL
II. Progression of measurable disease, or progression of non measurable disease as defined by:
i. Soft tissue disease: The appearance of one or more new lesions, and/or unequivocal worsening of non measurable disease when compared to imaging studies acquired during castration therapy or against the precastration studies if there was no response, or ii. Bone disease: Appearance of two or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the pre castration studies if there was no response.
III. Increased uptake of pre existing lesions on bone scan does not constitute progression.
IV. Testosterone ≤ 50 ng/dL achieved via medical or surgical castration.
- Male subjects who are fertile agree to use an acceptable form of birth control, defined as abstinence, barrier or other acceptable, effective contraceptive method throughout the study period. A second form of barrier birth control must be utilized if a subject's partner is using oral contraception until at least seven days after the last injection.
- Karnofsky performance is ≥ 50
Adequate hematologic, renal and liver function:
- WBC ≥ 2.0×103/mm3 (ANC > 1.0 x 103 mm3)
- Platelet count ≥ 75×103/mm3
- Hemoglobin ≥ 9.0 g/dL
- Creatinine ≤ 2.5 mg/dL
- Total bilirubin ≤ 2x ULN
- AST, ALT ≤ 5x ULN
Exclusion Criteria:
- Karnofsky performance status of < 50
- Subject has received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants or 12 months for 125I implants
- Subject was administered a diagnostic radioisotope within 5 physical half lives of that radioisotope prior to study enrollment
- Subject has received an investigational compound and/or medical device or has been part of an investigational study within the past 30 days before enrollment into this study
- Any treatment with radiopharmaceuticals, e.g. Strontium 89 and Samarium 153 within 6 months prior to enrollment
- Ketoconazole or anti androgens (flutamide, nilutamide, bicalutamide) within 4 weeks prior to enrollment. Patients who demonstrate an antiandrogen withdrawal response, defined as a > 25% drop in PSA within 4 weeks (flutamide) or 6 weeks (nilutamide, bicalutamide) of stopping a non steroidal anti androgen, are not eligible until the PSA rises above the nadir observed after anti androgen withdrawal
- Initiation of bisphosphonate therapy within 28 days prior to enrollment. Patients taking bisphosphonates should not have their dosing regimen altered unless medically warranted in the interval between baseline scans and end of study
- Subject has any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow up examinations
- Subject is determined by the Investigator to be clinically unsuitable for the study
- If the subject has had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, diagnosis and location must be defined or be defined as clinically controlled or treated to complete response
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: Nerandomizované
- Intervenční model: Crossover Assignment
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Previous ProstaScint®
Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
|
Single 10 mCi intravenous injection
Ostatní jména:
Single 5 mCi intravenous injection
Ostatní jména:
|
Experimentální: No Previous ProstaScint®
Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
|
Single 10 mCi intravenous injection
Ostatní jména:
Single 5 mCi intravenous injection
Ostatní jména:
Single 5 mCi intravenous injection
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Estimate the imaging sensitivity and specificity of 10.0 mCi or 5.0 mCi of 123I MIP 1072 compared to 5 mCi of 111In capromab pendetide in subjects with metastatic prostate cancer by determining the presence and extent of the disease.
Časové okno: 24 hours post-injection
|
24 hours post-injection
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Examine the imaging sensitivity and specificity of 10.0 mCi or 5.0 mCi of 123I MIP 1072 compared to 5 mCi of 111In capromab pendetide on a per lesion basis in subjects with metastatic prostate cancer
Časové okno: Through 2 weeks post-injection
|
Through 2 weeks post-injection
|
To describe the safety of administering 10.0 mCi and 5.0 mCi of 123I MIP 1072 for the detection of metastatic prostate cancer
Časové okno: Through 2 weeks post-injection
|
Through 2 weeks post-injection
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Mack Roach, MD, University of California, San Francisco
- Vrchní vyšetřovatel: Jeffrey Dobkin, MD, Pacific Coast Imaging
- Vrchní vyšetřovatel: Stanley Goldsmith, MD, NY Presbyterian Hospital - Weill Cornell Medical Center
- Vrchní vyšetřovatel: Edward Coleman, MD, Duke University
- Vrchní vyšetřovatel: Arif Hussain, MD, University of Maryland
- Vrchní vyšetřovatel: Kevin Slawin, MD, Vanguard Urologic Research Foundation
- Vrchní vyšetřovatel: Samuel L Kipper, MD, West Coast Radiology Centerse
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- TX-P103
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na 123-I-MIP-1072
-
Molecular Insight Pharmaceuticals, Inc.Dokončeno
-
Molecular Insight Pharmaceuticals, Inc.National Cancer Institute (NCI)Staženo
-
Molecular Insight Pharmaceuticals, Inc.DokončenoRakovina prostatySpojené státy, Belgie, Itálie, Česká republika, Maďarsko, Holandsko, Polsko, Ruská Federace
-
Molecular Insight Pharmaceuticals, Inc.DokončenoRakovina prostatySpojené státy
-
Duke UniversityThe Derfner FoundationDokončeno
-
Duke UniversityAmerican Lung AssociationNáborDětská obezita | Dětské astmaSpojené státy
-
Duke UniversityNational Institutes of Health (NIH)Zatím nenabírámeObezita | Dětská obezita | Astma u dětí | Dětské astmaSpojené státy
-
Istanbul Medipol University HospitalÇanakkale Onsekiz Mart University; Mehmet Akif Ersoy Canakkale State HospitalDokončenoChronická obstrukční plicní nemocKrocan
-
Molecular Insight Pharmaceuticals, Inc.Dokončeno
-
Molecular Insight Pharmaceuticals, Inc.Dokončeno